Rapid Microbiology Testing Market

The global rapid microbiology testing market is projected to reach USD 9.00 billion by 2031 from USD 5.69 billion in 2026, at a CAGR of 9.6%. The adoption of rapid microbiology testing solutions is accelerating amid increasing pressure on healthcare, pharmaceutical, food, and environmental laboratories to deliver faster and more accurate microbial detection results. Rising concerns regarding antimicrobial resistance, hospital-acquired infections, product contamination, and stringent quality assurance requirements are driving demand for rapid and automated microbiology workflows. Laboratories are increasingly shifting from conventional culture-based methods toward molecular, immunological, and automated rapid testing platforms that reduce turnaround times, improve sensitivity, and support timely clinical and manufacturing decisions.

The competitive landscape of the rapid microbiology testing market is characterized by the presence of established microbiology and diagnostics companies, including bioMérieux (France), Waters Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), and Thermo Fisher Scientific, Inc. (US).  Market competition is increasingly centered on expanding automated testing portfolios, improving sensitivity and accuracy, and integrating molecular and AI-enabled microbiology solutions into laboratory workflows. Companies are actively focusing on product launches, regulatory approvals, strategic collaborations, and geographic expansion to strengthen their market presence. For instance, in April 2026, bioMérieux SA (France) launched the BIOFIRE SPOTFIRE rapid molecular microbiology testing platform designed for pharmaceutical quality control applications, enabling mycoplasma detection in less than one hour and supporting faster microbial contamination assessment. Similarly, in December 2025, Becton, Dickinson and Company (BD) (US) collaborated with Certest Biotec S.L. (Spain) to expand automated molecular pathogen detection capabilities in Europe through the integration of IVDR-certified STI diagnostic assays on the BD MAX system. Furthermore, regulatory support for faster microbial detection methods and the growing need for real-time quality monitoring in pharmaceutical and food manufacturing environments continue to create favorable commercial opportunities for the providers of rapid microbiology testing solutions.

To know about the assumptions considered for the study download the pdf brochure

bioMérieux (France)

bioMérieux (France) is a key player in the rapid microbiology testing market due to its strong portfolio of automated microbial identification, antimicrobial susceptibility testing, molecular diagnostics, and industrial microbiology solutions. The company has established a significant global presence through its VITEK, BIOFIRE, and BacT/ALERT platforms, which are widely adopted across clinical laboratories, pharmaceutical manufacturing, and food safety testing environments. bioMérieux’s continued focus on innovation, rapid pathogen detection, antimicrobial resistance monitoring, and automation-driven laboratory workflows strengthens its competitive position in the market. In addition, the company benefits from strong regulatory expertise, a broad customer base, and strategic investments in syndromic testing and quality control solutions, further reinforcing its leadership in this industry.

Waters Corporation (US)

Becton, Dickinson and Company (BD) combined its biosciences & diagnostic solutions business with Waters Corporation (US) in 2026, strengthening its presence in microbiology and diagnostic testing solutions, including products relevant to the rapid microbiology testing market. The company is considered a key player in this market due to its broad portfolio of automated microbiology systems, molecular diagnostics, specimen collection products, and microbial identification solutions used across hospitals, clinical laboratories, and pharmaceutical settings. BD’s strong global distribution network, established installed base, and continued investments in automation, antimicrobial resistance testing, and laboratory workflow efficiency support its competitive position in the market. In addition, the company benefits from strong regulatory capabilities and strategic innovation initiatives focused on improving speed, accuracy, and scalability in microbiology testing applications.

Market Ranking

BioMérieux (France) is a leading player in the rapid microbiology testing market due to its strong portfolio of automated microbial identification, blood culture, and molecular diagnostic platforms widely used across clinical and industrial microbiology laboratories. Waters Corporation (US) has strengthened its position in the market through the combination with BD’s biosciences & diagnostic solutions business, expanding its capabilities in microbiology, diagnostics, and laboratory automation solutions relevant to rapid testing applications. Danaher Corporation (US) remains a major participant owing to its broad life sciences and diagnostics portfolio, including molecular diagnostics, filtration technologies, and microbial quality testing systems through subsidiaries such as Beckman Coulter and Cepheid. These companies benefit from strong global distribution networks, recurring consumable demand, and continued investments in automation and faster microbial detection technologies.

Related Reports:

Rapid Microbiology Testing Market by Product (Instruments (Mass Spectrometers), Consumables), Method (Nucleic Acid-based), Application (Industrial Testing (Food & Beverage), Clinical Diagnosis), End User (Hospitals), & Region - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]